Home

Message from our CEO

812x408 Jeffrey Leiden_0.png

Jeffrey Leiden, Chairman, President and CEO

Latest Press Releases

Date Title and Summary
Toggle Summary Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)
Eligible patients in Scotland will immediately have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor LONDON --(BUSINESS WIRE)--Sep. 12, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that eligible cystic fibrosis
Toggle Summary Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11
BOSTON --(BUSINESS WIRE)--Sep. 10, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET . The audio portion of management’s remarks can be accessed
Toggle Summary Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes
-Semma’s unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients- -Semma to be acquired for $950 million in cash- BOSTON & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep.

Copyright West LLC. Minimum 15 minutes delayed.